Leukemia, Myeloid Clinical Trials

47 clinical trials for Leukemia, Myeloid across international registries, including 7 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• CIML NK Cells With Venetoclax for AML — RECRUITING · PHASE1
• Allo HSCT Using RIC and PTCy for Hematological Diseases — RECRUITING · PHASE2
• Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation — RECRUITING · PHASE1
• Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia — RECRUITING · PHASE1
• A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome — RECRUITING · PHASE1
• Breath Analysis for the Detection of Invasive Fungal Infections — RECRUITING
• Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction Therapy — RECRUITING · NA
• A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia — OTHER · PHASE2
• Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase — ACTIVE_NOT_RECRUITING · PHASE2
• Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation — COMPLETED · PHASE1
• Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia — NOT_YET_RECRUITING · PHASE1
• Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia — TERMINATED · PHASE1
• An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation — COMPLETED · PHASE3
• Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS — COMPLETED · PHASE1
• Studying Malnutrition And Sarcopenia In Older Adults With Acute Myeloid Leukemia — COMPLETED
• Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid Leukemia — COMPLETED · NA
• Natural Killer Cell (CYNK-001) Infusions in Adults with AML — TERMINATED · PHASE1
• CD155 Expression in Acute Myeloid Leukemia — COMPLETED
• ELN 2022 in MENAFC ( Middle Eastern or North Coast of Africa ) Patients With Newly AML — OTHER
• Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG — COMPLETED · PHASE1
• Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia — OTHER · PHASE1
• CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia — OTHER · PHASE1
• A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy — TERMINATED · PHASE1
• Endogenous Retroviruses in Acute Myeloid Leukemia — WITHDRAWN
• Family Caregiver Ambassador Support for Family Caregivers of Patients With Hematological Disease — COMPLETED · NA
• A Multicentre, Retrospective Study to Evaluate the Outcome of HSCT Mismatch Unrelated Donors — COMPLETED
• A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML — OTHER · PHASE2
• Efficacy of FLAG Regimen for the Treatment of Patients With AML — OTHER
• Analyses of Human Samples Collected in Clinical Trials — COMPLETED
• Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease — TERMINATED · PHASE1
• A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia — COMPLETED · PHASE2
• Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML — TERMINATED · PHASE3
• Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders — COMPLETED · PHASE2
• Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome — COMPLETED · PHASE2
• Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI — COMPLETED · PHASE1
• Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid Malignancies — OTHER · PHASE2
• Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia — COMPLETED · PHASE2
• High Dose Donor Hematopoietic Stem Cell Infusion for Relapsed/Refractory AML — OTHER · PHASE1
• Biomarker To Evaluate Protein Profiles of Neutropenic Fever/Infection With Acute or Chronic Leukemias — COMPLETED
• Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS — COMPLETED · PHASE2
• Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients — COMPLETED · PHASE3
• Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation — COMPLETED · PHASE2
• Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes — COMPLETED · PHASE2
• Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia — COMPLETED · PHASE2
• T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation — TERMINATED · PHASE3
• A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia — COMPLETED · PHASE1
• Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML) — COMPLETED · PHASE1

Refine this search